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A recently published article (1) shows that ZEB1, one of 
the pivotal transcription factors involved in the induction 
of epithelial-mesenchymal transition (EMT) in tumor cells, 
inhibits the expression of the proapoptotic factor B-cell 
lymphoma (BCL) 2-interacting mediator of cell death (BIM) 
by binding directly to the BIM promoter and repressing 
its transcription. This mediates the resistance of epidermal 
growth factor receptor (EGFR)-mutant lung cancer cells with a 
mesenchymal phenotype towards EGFR inhibitor (EGFRi)-
induced apoptosis. These results are of considerable interest 
both in terms of our knowledge about the fundamental 
mechanisms governing EMT-associated effects, as well as 
their potential therapeutic implications. In order to put the 
findings in a broader context we will briefly summarize our 
current knowledge about EMT and its effects.
Tumor cells that undergo EMT loose properties of 
epithelial cells like apicobasal axis of polarity and cell-cell 
adhesion and acquire properties of mesenchymal cells like 
loose three-dimensional organization and, consequently, 
increased motility (2). There are different settings where 
EMT can occur. First, in response to stressors from the 
tumor microenvironment like hypoxia, low pH, immune 
responses, mechanical stress and antitumor drugs (3). 
Second, stressor-promoted epigenetic chances that induce 
heritable effects allowing retention of the mesenchymal 
state even when the stressors are no longer present (4). 
Third, stimulus-independent activation of signaling 
pathways, owing to activating mutations or overexpression 
of pathway components (5).
A large number of intracellular signaling pathways 
has been reported being involved in EMT (2). These 
pathways regulate the expression of a cohort of EMT-
promoting transcription factors. These transcription factors 
can be classified on the basis of their ability to repress 
E-cadherin directly or indirectly, because loss of E-cadherin 
expression is considered a crucial event for tumor cells 
undergoing EMT (6,7). Direct repressors include: zinc 
finger proteins of the SNAIL superfamily, such as SNAI1/
SNAIL, SNAI2/SLUG and SNAI3; zinc finger and E-box 
binding proteins of the ZEB family, such as ZEB1 and 
ZEB2; the basic helix-loop-helix factor (bHLH) E47; and 
the Krüppel-like factor KLF8. Factors such as the bHLH 
TWIST proteins (TWIST1 and TWIST2), the homeobox 
proteins goosecoid and SIX1, the bHLH factor E2.2 and 
the forkhead-box protein FOXC2 repress E-cadherin 
transcription indirectly. 
EMT, however, is not a unidirectional event. In fact, the 
EMT program is activated reversibly, permitting tumor cells 
to revert back to more epithelial states via mesenchymal-
epithelial transition (8). 
From a practical (clinical, prognostic) point-of-view 
the most important aspect of tumor cell EMT lies in its 
biological effects. Thus, acquisition of increased motility 
leads to increased invasiveness, which favors dissemination 
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of tumor cells to distant sites and formation of metastases. 
In addition, tumor cells become resistant to apoptosis and 
antitumor drugs, contribute to immunosuppression, and act 
as cancer stem-like cells (CSCs) (2). 
It can be immediately appreciated that these are exactly 
those biological properties that make tumors resistant 
to cures and are responsible for the vast majority of 
deaths among tumor patients. Hence the importance 
of understanding the basic mechanisms that leads to 
the biological effects of EMT in order to identify novel 
therapeutic approaches that address these effects. 
Now, where lies the relevance of the findings reported 
by Song et al. (1)? Beforehand, it is important to point out 
that, regarding the EMT of tumor cells, we know quite a 
lot about the signals that induce EMT (hereafter, the “input 
signals”), but we know relatively little about the signals that 
leads to the biological effects of EMT (the “output signals”). 
Are the input signals able to act also as output signals 
or, stated differently, are the biological effects a direct 
consequence of EMT or are additional signals required for 
this purpose? The work of Song et al. (1) gives a significant 
contribution to our understanding of this aspect.
Taking advantage of models of EMT-induced resistance 
to EGFRi in EGFR-mutant lung cancers, they observed that 
mesenchymal EGFR-mutant lung cancer cells are resistant 
to EGFRi-induced apoptosis via insufficient expression 
of the proapoptotic protein BIM, thereby preventing cell 
death despite potent suppression of oncogenic signaling. 
Insufficient expression of BIM was the consequence of 
direct binding of the EMT transcription factor ZEB1 to 
the BIM promoter and, consequently, to the repression 
of transcription. Increasing free intracellular BIM levels 
through derepression of its expression by depletion of ZEB1 
or treatment with the BCL-2 homology domain 3 (BH3) 
mimetic ABT-263 led to resensitization of mesenchymal 
EGFR-mutant cancer cells to EGFRi. The relationship 
between EMT and loss of BIM was not restricted to EGFR-
mutant lung cancers, as it was also observed in KRAS-
mutant lung cancers and large datasets, including different 
cancer subtypes. The authors point out, however, that low 
BIM is likely only one of multiple mechanisms whereby 
mesenchymal EGFR-mutant cancers are less sensitive to 
tyrosine kinase inhibitors like EGFRi.
These results are consistent with the view whereby input 
signals act also as output signals. Thus, ZEB1, a pivotal 
EMT transcription factor, is also directly responsible for 
the induction of resistance to EGFRi in EGFR mutant 
lung cancer cells. Whether this holds true also for other 
biological effects of EMT is an open question, but there 
are indications that this is not necessarily the case. Thus, 
it has been reported that EMT induces chemoresistance 
in pancreatic and lung cancer, but is not required for 
metastasis (9,10). In light of the results of Song et al. (1), 
this suggests that an input signal is sufficient to induce 
resistance to drug (EGFRi)-induced apoptosis, but other 
signals may be necessary to induce metastasis. It has been 
previously reported that ZEB1 contributes also to metastasis 
formation in lung cancer models, in particular as regards 
the establishment of a tumor microenvironment permissive 
for metastasis formation (11). On these bases one may then 
conclude that ZEB1 represents a necessary and sufficient 
condition for the induction of drug resistance, at least as 
regards EGFRi in EGFR mutant lung cancer cells, but a 
necessary, yet not sufficient condition for metastatization. 
In the latter case, one or more supplementary factors may 
be required in order to achieve sufficiency for metastasis 
formation and these factors may not be necessarily captured 
in a single tumor model. Thus, for example, acquisition of 
an EMT-induced procoagulant state has been reported to 
contribute to metastasis formation (12).
In addition to this principal finding, this article reports 
other results of considerable interest. First, it is shown 
that induction of EMT did not change the ability of 
EGFRi to down-regulate EGFR phosphorylation or 
downstream signaling pathways like the phosphoinositide 
3-kinase (PI3K)/Akt and extracellular-regulated kinase 
(ERK) pathways. This is despite the markedly reduced 
ability of EGFRi to induce apoptosis. This suggests that 
these signaling pathways are not involved in the resistance 
to EGFRi in EGFR-mutant lung cancer cells. This is 
surprising as one of the above pathways, PI3K/Akt, has 
even been proposed to be a crucial node for EMT induction 
and point of convergence for other EMT-inducing 
pathways (13). There are two possibilities to explain these 
findings. First, signaling pathways like PI3K/Akt may 
well be involved in the induction of EMT, but may play 
no further role in the maintenance of a mesenchymal 
phenotype and one or more of its biological effects (2). 
Second, a given EMT state is a mosaic-like composition 
and the assembly of different pieces give rise to different 
phenotypic pictures along a continuum from a fully 
epithelial to a fully mesenchymal phenotype (8). The tumor 
microenvironment would play a key role in the overall 
composition of the EMT mosaic (14). According to this 
view it would not come to surprise if different signaling 
pathways contribute to a given mosaic and, in certain 
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conditions, one or more of the EMT-inducing pathways 
may play a negligible role, while playing a predominant role 
in other conditions. Recent results showing that multiple 
tumor subpopulations associated with different EMT 
stages display differences in cellular plasticity, invasiveness 
and metastatic potential, while presenting different 
transcriptional and epigenetic landscapes appear consistent 
with this view (14).
Third, further results (1) suggest that mesenchymal 
EGFR mutant lung cancer cells preexist to and are positively 
selected by drug (EGFRi) treatment (Figure 1). These cells 
may then reacquire the ability to grow via a mutational 
event affecting growth signaling pathways. The possibility 
that antitumor drugs may positively select preexisting 
mesenchymal tumor cells has already been proposed (15). 
Incidentally, the observation of preexisting mesenchymal 
EGFR mutant lung cancer cells may also explain the 
apparent paradox that EGFRi have been reported to 
prevent EMT induction in tumor cells (16). In fact, EGFRi 
may be able to inhibit the EMT in cells with an epithelial 
phenotype, but may not be able to do so in cells that have 
already undergone an EMT, i.e., to reverse an established 
mesenchymal phenotype. The preexistence of drug-
resistant, mesenchymal tumor cells suggests the possibility 
of a combined therapeutic approach using compounds 
that act on mesenchymal tumor cells in order to prevent 
tumor cell regrowth and compounds that act on epithelial 
tumor cells. This raises the question as to which would be 
the most appropriate drug class to inhibit and/or deplete 
mesenchymal tumor cells. Many classes of drugs with 
the potential to act as inhibitors of EMT induction and/
or maintenance of a mesenchymal phenotype have been 
described (2,8,17). However, if we consider the possibility 
that different signaling pathways induce different EMT 
transition states that display different phenotypic profiles, 
then it may be very difficult to identify a class of drugs 
active in every setting where EMT occurs. Of course, 
also in this case one may expect making progress in the 
identification of biomarkers predicting the contribution of 
individual signaling pathways in the induction of a given 
EMT phenotype. On the other hand, the unambiguous 
identification of mediators of resistance towards EGFRi 
in EGFR mutant lung cancer cells (ZEB1 and BIM), as 
described in the article of Song et al. (1), paves the way for 
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Figure 1 Mechanism of Resistance towards EGFRi in Mesenchymal EGFR-Mutant Lung Cancer Cells towards EGFRi. EGFR-mutant lung 
cancers are constituted, to varying degrees, by tumor cells of predominantly epithelial phenotype, and lung cancer cells of predominantly 
mesenchymal phenotype. Cells with predominantly mesenchymal phenotype express high levels of the EMT transcriptional regulator 
ZEB1. ZEB1 binds directly to the promoter of the gene encoding the antiapoptotic protein B and represses its transcription. Low levels of 
BIM promote resistance to EGFRi and, possibly also to other antitumor drugs. Lung cancer cells with a predominantly epithelial phenotype 
express unrepressed levels of BIM and promote apoptosis towards EGFRi. BIM, BCL-2-interacting mediator of cell death; EGFR, 
epidermal growth factor receptor; EGFRi, EGFR inhibitor(s); EMT, epithelial-mesenchymal transcription.
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the design and testing of compounds that inhibit (ZEB1) or 
increase the intracellular levels (BIM) of these mediators. 
In the case of ZEB1, a transcription factor, this appears a 
challenging but, in perspective, not impossible task. The 
other possibility, i.e., to increase the intracellular levels of 
the proapoptotic factor BIM appears more feasible in the 
shorter term and the authors of this article have shown that 
this can be achieved in experimental models through the 
use of the BH3 mimetic ABT-263 that competes with BIM 
for binding to BCL extra large (xL).
Overall, these are important results which raise several 
questions. First of all, the present findings bear on 
EGFR and KRAS mutant lung cancer cells and show that 
EMT-mediated resistance to EGFRi can be overcome 
by increasing levels of free intracellular BIM. Then, do 
these conclusions hold true also for other classes of drugs 
like chemotherapeutic drugs, radiotherapeutics or even 
immune checkpoint inhibitors, given that tumor cell-
associated immune checkpoint molecules are able to induce 
EMT (18)? Second, do these conclusions hold true also 
for other cancer types beyond the herein considered lung 
(non-small cell lung) cancer? Preliminary answers to these 
questions can be obtained in suitable animal models using 
different cancer types and different classes of antitumor 
drugs. Third, as pointed out by the authors, it is likely that 
low BIM is only one mechanism of resistance of EGFR-
mutant cancers to EGFRi. How, then, can we predict 
whether a cancer is potentially sensitive to therapeutics that 
increase free intracellular levels of BIM? The identification 
of one or more predictable biomarkers would be the 
obvious solution to this problem. 
 In conclusion, the work of Song et al. (1) starts 
elucidating some heretofore unexplained aspects related to 
EMT-associated biological effects, in particular as regards 
the resistance of tumor cells to EGFRi in EGFR mutant 
lung cancer cells. In the models that were investigated this 
appears to be mediated by the transcription factor ZEB1 
leading to down-regulation of the proapoptotic factor BIM. 
Possibly, these conclusions may also apply to resistance 
towards other classes of antitumor drugs. Importantly, 
this article offers also ways for therapeutically addressing 
this resistance, through enhancing free, intracellular levels 
of down-regulated BIM. As is normal for an informative 
article, the results that are reported raise many new 
questions to be addressed in forthcoming years. In any case, 
it appears of particular encouragement that some of the 
findings can be rapidly tested in clinical trials.
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